Cynata Therapeutics Ltd (AU:CYP) — Market Cap & Net Worth
Market Cap & Net Worth: Cynata Therapeutics Ltd (CYP)
Cynata Therapeutics Ltd (AU:CYP) has a market capitalization of $53.76 Million (AU$75.99 Million) as of May 5, 2026. Listed on the AU stock exchange, this Australia-based company holds position #21616 globally and #776 in its home market, demonstrating a -8.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cynata Therapeutics Ltd's stock price AU$0.32 by its total outstanding shares 237454369 (237.45 Million). Analyse Cynata Therapeutics Ltd cash flow conversion to see how efficiently the company converts income to cash.
Cynata Therapeutics Ltd Market Cap History: 2015 to 2026
Cynata Therapeutics Ltd's market capitalization history from 2015 to 2026. Data shows change from $59.46 Million to $53.76 Million (-3.74% CAGR).
Cynata Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cynata Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
30.75x
Cynata Therapeutics Ltd's market cap is 30.75 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $122.28 Million | $1.10 Million | -$4.94 Million | 111.19x | N/A |
| 2017 | $103.87 Million | $1.75 Million | -$4.55 Million | 59.39x | N/A |
| 2018 | $217.76 Million | $1.38 Million | -$4.57 Million | 158.36x | N/A |
| 2019 | $174.21 Million | $1.31 Million | -$8.47 Million | 133.13x | N/A |
| 2020 | $115.09 Million | $7.01 Million | -$3.64 Million | 16.41x | N/A |
| 2021 | $91.57 Million | $1.55 Million | -$7.69 Million | 59.23x | N/A |
| 2022 | $50.40 Million | $7.77 Million | -$5.45 Million | 6.49x | N/A |
| 2023 | $21.00 Million | $1.65 Million | -$14.28 Million | 12.70x | N/A |
| 2024 | $40.32 Million | $2.32 Million | -$9.74 Million | 17.41x | N/A |
| 2025 | $57.96 Million | $1.89 Million | -$9.39 Million | 30.75x | N/A |
Competitor Companies of CYP by Market Capitalization
Companies near Cynata Therapeutics Ltd in the global market cap rankings as of May 5, 2026.
Key companies related to Cynata Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Cynata Therapeutics Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Cynata Therapeutics Ltd's market cap moved from $59.46 Million to $ 53.76 Million, with a yearly change of -3.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$53.76 Million | -7.25% |
| 2025 | AU$57.96 Million | +43.75% |
| 2024 | AU$40.32 Million | +92.00% |
| 2023 | AU$21.00 Million | -58.33% |
| 2022 | AU$50.40 Million | -44.95% |
| 2021 | AU$91.57 Million | -20.44% |
| 2020 | AU$115.09 Million | -33.94% |
| 2019 | AU$174.21 Million | -20.00% |
| 2018 | AU$217.76 Million | +109.66% |
| 2017 | AU$103.87 Million | -15.06% |
| 2016 | AU$122.28 Million | +105.65% |
| 2015 | AU$59.46 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of Cynata Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $53.76 Million USD |
| MoneyControl | $53.76 Million USD |
| MarketWatch | $53.76 Million USD |
| marketcap.company | $53.76 Million USD |
| Reuters | $53.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cynata Therapeutics Ltd
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host … Read more